CCA
CRXT

Cruiser Capital Advisors’s Clarus Therapeutics Holdings, Inc. Common Stock CRXT Stock Holding History

Cruiser Capital Advisors’s Portfolio CRXT Stock Details CRXT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-20,000
Closed -$201K – 62
2021
Q1 		$201K Buy
+20,000
New +$202K 0.18% 36

Other funds holding CRXT

KIM
Karpus Investment Management Pittsford, New York $3.21B AUM 6.83% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 22.54% 1-Year Est. Return
SCM
Saba Capital Management New York $3.62B AUM 13% 1-Year Est. Return
YCM
Yakira Capital Management Westport, Connecticut $342M AUM 26.97% 1-Year Est. Return
ASM
ATW SPAC Management New York $79.2M AUM 10.67% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Cruiser Capital Advisors's CRXT Position: Q2 2021 in Review

Cruiser Capital Advisors sold out of Clarus Therapeutics Holdings, Inc. Common Stock (CRXT) in Q2 2021, closing a stake of 20,000 shares — an estimated $201K sold.

Cruiser Capital Advisors first reported a position in CRXT in Q1 2021 and held it in 1 quarter. The position peaked at $201K in Q1 2021. 33 funds tracked by Wall St. Rank hold CRXT as of Q2 2021.

  • Cruiser Capital Advisors reported no remaining Clarus Therapeutics Holdings, Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
  • Cruiser Capital Advisors sold 20,000 Clarus Therapeutics Holdings, Inc. Common Stock shares in Q2 2021, an estimated $201K.
  • Cruiser Capital Advisors first reported a position in Clarus Therapeutics Holdings, Inc. Common Stock in Q1 2021 and held it in 1 quarter.
  • Cruiser Capital Advisors's Clarus Therapeutics Holdings, Inc. Common Stock position peaked at $201K in Q1 2021.
  • 33 funds tracked by Wall St. Rank held Clarus Therapeutics Holdings, Inc. Common Stock as of Q2 2021.

Based on Cruiser Capital Advisors's 13F filing for Q2 2021, filed 16 Aug 2021.